Previous 10 | Next 10 |
Image source: The Motley Fool. Pulse Biosciences, Inc. (NASDAQ: PLSE) Q2 2020 Earnings Call Aug 10, 2020 , 4:30 p.m. ET Operator Continue reading
Pulse Biosciences, Inc. (PLSE) Q2 2020 Earnings Conference Call August 10, 2020, 04:30 PM ET Company Participants Philip Taylor - IR Darrin Uecker - President, CEO Ed Ebbers - EVP and General Manager of Dermatology Sandy Gardiner - EVP and CFO Conference Call Participants ...
Pulse Biosciences (NASDAQ: PLSE ) : Q2 Non-GAAP EPS of -$0.53 misses by $0.03 . More news on: Pulse Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter ended June 30, 2020. Recent Highlights Completed the CellFX ® System GLP...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation TM (NPS™) technology, announced today the appointment of Richard van den Broek to its board of directors. ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, announced today it will report financial results for the second quarter 2020 after market close on Monday, August 10, 2020. Company management will host a ...
-- New Category Created for Non-Thermal Cellular Specific NPS Technology in Original ASLMS Program of Scientific Abstracts and Posters Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, today announc...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, announced today the closing of its oversubscribed rights offering and the final results thereof. The rights offering resulted in the sale of 4,2...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, announced today further details of its rights offering, which expired on June 8, 2020. Based on a preliminary tabulation by Broadridge Corporate...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced preliminary results of its rights offering, which expired at 5:00 p.m. Eastern Time on June 8, 2020 (the “Expiration Date...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company managemen...
2024-07-15 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...